Adicet Bio, Inc. (ACET) Stock

About Adicet Bio, Inc.

Adicet Bio, Inc. is led by CEO Chen Schor, employs 152 people, headquartered in US, publicly traded since 2018.

Adicet Bio, Inc. (ACET) stock trades at $3.99 with a market capitalization of $37.35M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.57, reflecting a net loss over the last twelve months, price-to-book of 0.58, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.99 and $17.44, and currently trades 77.1% below its 52-week high.

On profitability, Adicet Bio, Inc. generates a return on equity (ROE) of -74.90% (negative, reflecting a net loss), return on capital employed of -79.68%.

Adicet Bio, Inc. by the numbers, 2016–2025

Between 2016 and 2025 Adicet Bio, Inc. reported revenue of $547.0M rising to $0, a change of -100.0% across 10 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-117.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-99.0M.

Borrowings fell from $119.0M to $15.0M, cash from operations was $-95.0M in the latest year, positive in 1 of the last 10.

Return on equity has averaged -52.9% over five years, and was -73.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Adicet Bio, Inc. (ACET) — frequently asked questions